Literature DB >> 20527043

Adjusting transgene expression levels in lymphocytes with a set of inducible promoters.

Christina Danke1, Xandra Grünz, Jürgen Wittmann, Andreas Schmidt, Siamak Agha-Mohammadi, Olaf Kutsch, Hans-Martin Jäck, Wolfgang Hillen, Christian Berens.   

Abstract

BACKGROUND: Inducible gene expression systems are powerful research tools and could be of clinical value in the future, with lymphocytes being likely prime application targets. However, currently available regulatable promoters exhibit variation in their efficiency in a cell line-dependent-manner and are notorious for basal leakiness or poor inducibility. Data concerning the regulatory properties of different inducible promoters are scarce for lymphocytes. In the present study, we report a comprehensive analysis of how various inducible promoters perform and how their combination with a transsilencer and a reverse transactivator can result in optimally controlled gene expression in T-cells.
METHODS: The performance of the tetracycline-regulated (Tet)-inducible promoters Tet-responsive element (TRE), mouse mammary tumor virus (MMTV)/TRE, TREtight and second generation TRE (SG/TRE) was compared in several B-cell lines and in Jurkat T-cells using transient transfections in combination with Tet-On. To monitor transgene expression in a Jurkat cell line containing a transsilencer and a reverse transactivator, expression cassettes encoding enhanced green fluorescent protein, CD123 or a constitutively active, cytotoxic caspase-3 were flanked with insulators and stably integrated. The performance of TREtight and SG/TRE was furthermore analysed in transiently transfected primary CD4(+) human T-cells.
RESULTS: The promoters exhibit greatly diverging characteristics. MMTV/TRE permits moderate, TRE and TREtight permits intermediate and SG/TRE permits very high expression levels. TRE and SG/TRE are leaky, whereas MMTV/TRE and TREtight provide stringent expression control. Tetracycline derivatives add flexibility to transgene expression by introducing intermediate expression levels.
CONCLUSIONS: The different expression profiles of the promoters increase the flexibility to adjust transgene expression levels. The promoters provide an additional option to optimize system performance for many applications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20527043     DOI: 10.1002/jgm.1461

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  18 in total

1.  An outer membrane channel protein of Mycobacterium tuberculosis with exotoxin activity.

Authors:  Olga Danilchanka; Jim Sun; Mikhail Pavlenok; Christian Maueröder; Alexander Speer; Axel Siroy; Joeli Marrero; Carolina Trujillo; David L Mayhew; Kathryn S Doornbos; Luis E Muñoz; Martin Herrmann; Sabine Ehrt; Christian Berens; Michael Niederweis
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-21       Impact factor: 11.205

2.  Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling.

Authors:  Christian Berens; Stephanie Bisle; Leonie Klingenbeck; Anja Lührmann
Journal:  J Vis Exp       Date:  2015-06-25       Impact factor: 1.355

Review 3.  A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.

Authors:  Abdelwahed Chtarto; Olivier Bockstael; Terence Tshibangu; Olivier Dewitte; Marc Levivier; Liliane Tenenbaum
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

4.  Phosphorylation of CDC25A on SER283 in late S/G2 by CDK/cyclin complexes accelerates mitotic entry.

Authors:  Laurent Mazzolini; Anaïs Broban; Carine Froment; Odile Burlet-Schiltz; Arnaud Besson; Stéphane Manenti; Christine Dozier
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

Review 5.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

6.  Improved Tet-responsive promoters with minimized background expression.

Authors:  Rainer Loew; Niels Heinz; Mathias Hampf; Hermann Bujard; Manfred Gossen
Journal:  BMC Biotechnol       Date:  2010-11-24       Impact factor: 2.563

7.  NAD+ Depletion Triggers Macrophage Necroptosis, a Cell Death Pathway Exploited by Mycobacterium tuberculosis.

Authors:  David Pajuelo; Norberto Gonzalez-Juarbe; Uday Tak; Jim Sun; Carlos J Orihuela; Michael Niederweis
Journal:  Cell Rep       Date:  2018-07-10       Impact factor: 9.423

8.  MAP3K11 is a tumor suppressor targeted by the oncomiR miR-125b in early B cells.

Authors:  U Knackmuss; S E Lindner; T Aneichyk; B Kotkamp; Z Knust; A Villunger; S Herzog
Journal:  Cell Death Differ       Date:  2015-07-03       Impact factor: 15.828

9.  Strong negative feedback from Erk to Raf confers robustness to MAPK signalling.

Authors:  Raphaela Fritsche-Guenther; Franziska Witzel; Anja Sieber; Ricarda Herr; Nadine Schmidt; Sandra Braun; Tilman Brummer; Christine Sers; Nils Blüthgen
Journal:  Mol Syst Biol       Date:  2011-05-24       Impact factor: 11.429

10.  A novel MCF-10A line allowing conditional oncogene expression in 3D culture.

Authors:  Ricarda Herr; Franziska U Wöhrle; Christina Danke; Christian Berens; Tilman Brummer
Journal:  Cell Commun Signal       Date:  2011-07-13       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.